Private Equity Looking for Interns - Gilde Healthcare

Private Equity Looking for Interns

22. August 2018

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities.

Given the compact investment team, the intern will have the opportunity to take an integral role in a deal team. The intern will have the opportunity to engage in many parts of the investment process, with an emphasis on the deal origination phase. Strong analytical skills, an excellent track record and an entrepreneurial spirit are therefore required. We assume fluency in English and either Dutch or German. A previous internship in corporate finance, strategy consultancy or private equity is appreciated. You will work 3 (or more) months in the city of Utrecht as member of our investment team.

More information on Gilde Healthcare: gildehealthcare.com
More information on this position: Mr. T. Klein Robbenhaar, robbenhaar@gildehealthcare.com
When interested, please send your resume and concise motivational email and we will be in contact with you.

 

 

Mehr neuigkeiten

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17. Oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15. Oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14. Oktober 2025